4.7 Review

Update on the Role and Utility of Extracellular Vesicles in Hematological Malignancies

期刊

STEM CELLS
卷 40, 期 7, 页码 619-629

出版社

OXFORD UNIV PRESS
DOI: 10.1093/stmcls/sxac032

关键词

extracellular vesicles; hematological malignancies; exosomes; microvesicles; tumor microenvironment

资金

  1. Laboratorio Universitario di Ricerca Medica (L.U.R.M.) of University of Verona

向作者/读者索取更多资源

Extracellular vesicles (EVs) are released by cells and contain various bioactive molecules, playing a crucial role in intercellular communication and biological processes. In hematological malignancies, EVs contribute to tumor development, drug resistance, and bone marrow microenvironment modulation. EVs have potential as diagnostic biomarkers, therapeutic targets, and drug carriers.
Extracellular vesicles (EVs) are membrane-surrounded cellular particles released by virtually any cell type, containing numerous bioactive molecules, including lipids, proteins, and nucleic acids. EVs act as a very efficient intercellular communication system by releasing their content into target cells, thus affecting their fate and influencing several biological processes. EVs are released both in physiological and pathological conditions, including several types of cancers. In hematological malignancies (HM), EVs have emerged as new critical players, contributing to tumor-to-stroma, stroma-to-tumor, and tumor-to-tumor cell communication. Therefore, EVs have been shown to play a crucial role in the pathogenesis and clinical course of several HM, contributing to tumor development, progression, and drug resistance. Furthermore, tumor EVs can reprogram the bone marrow (BM) microenvironment and turn it into a sanctuary, in which cancer cells suppress both the normal hematopoiesis and the immunological antitumor activity, conferring a therapy-resistant phenotype. Due to their physicochemical characteristics and pro-tumor properties, EVs have been suggested as new diagnostic biomarkers, therapeutic targets, and pharmacological nanocarriers. This review aims to provide an update on the pathogenetic contribution and the putative therapeutic utility of EVs in hematological diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据